ZMS1076
Anti-SARS-CoV-1/2 S Protein Antibody, clone 2B3E5 ZooMAb® Mouse Monoclonal
recombinant, expressed in HEK 293 cells
Synonym(s):
Coronavirus S protein, Cov-2 S protein, E2, Peplomer protein, S glycoprotein, SARS-CoV 1/2 Spike glycoprotein
Sign Into View Organizational & Contract Pricing
All Photos(10)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Recommended Products
biological source
mouse (recombinant)
Quality Level
recombinant
expressed in HEK 293 cells
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
2B3E5, recombinant monoclonal
product line
ZooMAb® learn more
form
lyophilized
mol wt
calculated mol wt 139.13 kDa (SARS-CoV)
calculated mol wt 141.18 kDa (SARS-CoV-2)
observed mol wt ~230 kDa
species reactivity
SARS virus
packaging
antibody small pack of 25 μL
greener alternative product characteristics
Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.
enhanced validation
recombinant expression
Learn more about Antibody Enhanced Validation
sustainability
Greener Alternative Product
technique(s)
ELISA: suitable
affinity binding assay: suitable
flow cytometry: 1 μg/mL
western blot: 1:5,000
isotype
IgG2aκ
greener alternative category
, Aligned
shipped in
ambient
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
SARS coronavirus ... S(43740568)
SARS virus ... S(1489668)
General description
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.
Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.
Learn more about ZooMAb here.
Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.
Learn more about ZooMAb here.
Specificity
Clone 2B3E5 is a ZooMAb mouse recombinant antibody that specifically detects SARS-CoV-1/2 Spike protein. It targets an epitope within the extracellular domain.
Immunogen
Recombinant fragment corresponding to full-length extracellular domain from SARS-CoV virus spike protein.
Application
Affinity Binding Assay: This antibody bound recombinant extracellular domain of Spike protein with a KD of 3.8 x 10-7 and with the recombinant receptor binding domain with a KD of 4.4 x 10-7.
Flow Cytometry Analysis: 1 μg/mL from a representative lot detected SARS-CoV-1/2 S protein in Transfected 293 cells (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).
Western Blotting Analysis: 1 μg/mL from a representative lot detected SARS-CoV-1/2 S Protein in Vero E6 cells +/- SARS-Cov-2 infection (Courtesy of Jeff Johnson Laboratory, Icahn School of Medicine at Mount Sinai (ISMMS).
ELISA Analysis: A multiple Dilution from a representative lot detected SARS-CoV-1/2 S Protein in S1 fusion protein (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Flow Cytometry Analysis: 1 μg/mL from a representative lot detected SARS-CoV-1/2 S protein in Transfected 293 cells (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).
Western Blotting Analysis: 1 μg/mL from a representative lot detected SARS-CoV-1/2 S Protein in Vero E6 cells +/- SARS-Cov-2 infection (Courtesy of Jeff Johnson Laboratory, Icahn School of Medicine at Mount Sinai (ISMMS).
ELISA Analysis: A multiple Dilution from a representative lot detected SARS-CoV-1/2 S Protein in S1 fusion protein (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-SARS-CoV-1/2 S Protein, clone 2B3E5 ZooMAb, Cat. No. ZMS1076, is a recombinant Mouse monoclonal antibody that detects SARS-CoV-1/2 Spike (S) protein and is tested for use in Affinity Binding Assay, ELISA, Flow Cytometry, and Western Blotting.
Target description
SARS-CoV-1/2 Spike glycoprotein (UniProt: P59594/P0DTC2; also known as S glycoprotein, E2, Peplomer protein) is encoded by the S gene (Gene ID: 1489668/43740568) in SARS-CoV-1/2 virus. The SARS-CoV-2 is a positive-strand RNA virus that causes severe respiratory syndrome in human. The mature SARS-CoV-2 contains 4 structural proteins: Envelope (E), Membrane (M), Nucleocapsid (N), and the Spike protein (S). E and M proteins help in viral assembly and N protein is needed for RNA synthesis. The S protein is a single-pass type I, homotrimeric, membrane glycoprotein that is responsible for virus binding and entry into host cell. It is synthesized with a signal peptide (aa 1-12), which is subsequently cleaved off to generate the mature protein that contains an extracellular domain (aa 13-1213), a transmembrane domain (aa 1214-1234), and a cytoplasmic domain 1235-1273). The S protein is further processed into S1 (aa 13-685) and S2 (aa 686-1273) subunits by host cell furin. The presence of a furin polybasic cleavage site in S protein from SARS-CoV-2 sets it apart from S protein in SARS-CoV that possesses a monobasic S1/S2 cleavage site. The S1 subunit has the receptor binding domain (RBD; aa 319-541) that mediates entry of SARS-CoV-2 into sensitive cells through the peptidase domain of host Angiotensin-converting enzyme 2 (ACE2) with high affinity (KD = 15 nM). The S2 protein, which is reported to be well conserved, is responsible for membrane fusion. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
Physical form
Purified mouse monoclonal antibody IgG2a in buffer containing PBS with 5% Trehalose without preservatives
Reconstitution
300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Data presented is the available current product information and provided as-is. These products have not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.
Data presented is the available current product information and provided as-is. These products have not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tarun Mishra et al.
Life science alliance, 5(7) (2022-03-18)
Breakthrough infections by emerging SARS-CoV-2 variants raise significant concerns. Here, we sequence-characterized the spike gene from breakthrough infections that corresponded to B.1.617 sublineage. Delineating the functional impact of spike mutations revealed that N-terminal domain (NTD)-specific E156G/Δ157-158 contributed to increased infectivity
Sachiko T Homma et al.
Biomedicines, 12(7) (2024-07-27)
Muscle fatigue represents the most prevalent symptom of long-term COVID, with elusive pathogenic mechanisms. We performed a longitudinal study to characterize histopathological and transcriptional changes in skeletal muscle in a hamster model of respiratory SARS-CoV-2 infection and compared them with
Tarun Mishra et al.
Frontiers in cellular and infection microbiology, 11, 663688-663688 (2021-05-11)
The establishment of SARS CoV-2 spike-pseudotyped lentiviral (LV) systems has enabled the rapid identification of entry inhibitors and neutralizing agents, alongside allowing for the study of this emerging pathogen in BSL-2 level facilities. While such frameworks recapitulate the cellular entry
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo , D., et al.
Cell, 181, 1036-1045 (2020)
Daniel Blanco-Melo et al.
Cell, 181(5), 1036-1045 (2020-05-18)
Viral pandemics, such as the one caused by SARS-CoV-2, pose an imminent threat to humanity. Because of its recent emergence, there is a paucity of information regarding viral behavior and host response following SARS-CoV-2 infection. Here we offer an in-depth
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service